中华皮肤科杂志
中華皮膚科雜誌
중화피부과잡지
Chinese Journal of Dermatology
2015年
1期
54-56
,共3页
荨麻疹%随机对照试验%枸地氯雷他定%依匹斯汀
蕁痳疹%隨機對照試驗%枸地氯雷他定%依匹斯汀
담마진%수궤대조시험%구지록뢰타정%의필사정
Urticaria%Randomized controlled trials%Desloratadine citrate disodium%Epinastine
目的 探讨枸地氯雷他定和依匹斯汀治疗慢性荨麻疹的疗效和安全性.方法 随机、双盲、双模拟和对照研究.试验组服枸地氯雷他定胶囊每日1次,每次8.8 mg,对照组依匹斯汀胶囊每日1次,每次10 mg,均连续服用28 d.于用药后随访,观察疗效和不良反应.结果 入选病例157例,可评价疗效和安全性病例142例.经28 d治疗后,枸地氯雷他定组有效率81.16％、依匹斯汀组有效率78.08％,两组比较差异无统计学意义(P＞0.05).枸地氯雷他定组和对照组药物相关性不良反应发生率分别为13.89％和12.16％,两组比较差异无统计学意义(P＞0.05).结论 枸地氯雷他定治疗慢性荨麻疹安全有效.
目的 探討枸地氯雷他定和依匹斯汀治療慢性蕁痳疹的療效和安全性.方法 隨機、雙盲、雙模擬和對照研究.試驗組服枸地氯雷他定膠囊每日1次,每次8.8 mg,對照組依匹斯汀膠囊每日1次,每次10 mg,均連續服用28 d.于用藥後隨訪,觀察療效和不良反應.結果 入選病例157例,可評價療效和安全性病例142例.經28 d治療後,枸地氯雷他定組有效率81.16％、依匹斯汀組有效率78.08％,兩組比較差異無統計學意義(P＞0.05).枸地氯雷他定組和對照組藥物相關性不良反應髮生率分彆為13.89％和12.16％,兩組比較差異無統計學意義(P＞0.05).結論 枸地氯雷他定治療慢性蕁痳疹安全有效.
목적 탐토구지록뢰타정화의필사정치료만성담마진적료효화안전성.방법 수궤、쌍맹、쌍모의화대조연구.시험조복구지록뢰타정효낭매일1차,매차8.8 mg,대조조의필사정효낭매일1차,매차10 mg,균련속복용28 d.우용약후수방,관찰료효화불량반응.결과 입선병례157례,가평개료효화안전성병례142례.경28 d치료후,구지록뢰타정조유효솔81.16％、의필사정조유효솔78.08％,량조비교차이무통계학의의(P＞0.05).구지록뢰타정조화대조조약물상관성불량반응발생솔분별위13.89％화12.16％,량조비교차이무통계학의의(P＞0.05).결론 구지록뢰타정치료만성담마진안전유효.
Objective To evaluate the efficacy and safety of desloratadine citrate disodium versus epinastine for the treatment of chronic urticaria (CU).Methods A randomized,double-blind,double-dummy controlled clinical trial was conducted.Patients with CU were divided into test group and control group to be treated by oral desloratadine citrate disodium (8.8 mg/d) and epinastine (10 mg/d) respectively once a day for 28 days.All the patients were followed up after starting treatment.Therapeutic effect was evaluated,and adverse reactions were observed.Results One hundred and fifty-seven patients were enrolled in this study,and 142 patients were valid for evaluation of efficacy and safety at the end of study.After treatment for 28 days,there was no significant difference between the test group and control group in response rate (81.16 ％ vs.78.08 ％,P ＞ 0.05) or incidence rate of adverse reactions (13.89 ％ vs.12.16 ％,P＞ 0.05).Conclusion Desloratadine citrate disodium is effective and safe for the treatment of CU.
